For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on July 24th, 2024 | 06:30 CEST
BioNTech, Bayer, Vidac Pharma: Buy recommendations and potential worth billions
Can BioNTech shares stop the downward trend? A "Buy" recommendation gives hope. According to this recommendation, the shares of the German biotech flagship have the potential to double in value. Analysts believe a multiplication is possible for Vidac Pharma. The biotech company is pursuing a revolutionary approach in the fight against cancer, and the first drug has a revenue potential of over EUR 1 billion. Even though research is still ongoing, Vidac is not expensive with a market capitalization of less than EUR 10 million, and is a takeover candidate if the study data remain positive. Analysts do not currently see any impetus for an increase in Bayer's share price. However, shareholders should be ready for news from the pharmaceutical pipeline in the coming weeks. These are important for the DAX-listed company.
Read
Commented by Fabian Lorenz on July 23rd, 2024 | 06:50 CEST
70% with Evotec shares? Caution with BASF? Almonty Industries tempts investors to get in!
Will BASF miss market expectations in the second half of the year? Analysts believe so. The chemical giant's revenues are already expected to fall in the second quarter. So, should one sell the shares now? The Evotec share was bought yesterday. Analysts believe that the profit warning from Sartorius should not be overestimated and see over 70% upside potential. However, patience is required. The Almonty Industries share also appears too favourable. The commissioning of a huge tungsten mine is imminent, and not only companies such as Taiwan Semiconductor and Rheinmetall need the critical metal for their high-tech products. So, when will the share break out?
Read
Commented by Fabian Lorenz on July 17th, 2024 | 07:30 CEST
Siemens Energy share down 50%? Now time to buy Rheinmetall, Bayer, and Saturn Oil + Gas?
Can the Siemens Energy share halve in value? At least, that is what the analysts at Bernstein think, who have set a price target of EUR 15. After a strong rally, the focus is now back on the Company's problem areas, such as India. Rheinmetall, on the other hand, is recommended as a "Buy". Can the armaments group thus end its sideways movement? In an initial study, analysts see around 50% upside potential for Saturn Oil & Gas. The oil company intends to significantly increase its free cash flow in the coming years but is considered undervalued compared to its peers. Some analysts see even more potential. Analysts are cautious about Bayer shares. In addition to the well-known legal disputes, operational issues are also a burden.
Read
Commented by Fabian Lorenz on July 16th, 2024 | 07:15 CEST
Next share price jump? TUI, Aixtron, and Desert Gold
Is the Aixtron share about to make its next leap? The shock of the profit warning was digested with a rise of over 10%. Three analysts recommend the share as a "Buy". Desert Gold is also ripe for a new rally. After more than doubling in a short space of time at the beginning of the year, it consolidated textbook style. Will it soon jump to a new yearly high? The Company is certainly not expensive, and experts consider a gold price of USD 3,000 possible. Important drilling results are also on the horizon. TUI is currently performing well operationally. The summer season business is booming, and the bankruptcy of a competitor is providing additional momentum. Nevertheless, the share is trending sideways. Could the purchase of an island be the trigger?
Read
Commented by Fabian Lorenz on July 11th, 2024 | 06:55 CEST
Shares with breakthrough potential? Evotec, Varta, and Carbon Done Right Developments
Evotec is currently going from strength to strength. Yesterday, a partnership with pharmaceutical giant Pfizer boosted the share price. Will the resistance at EUR 10 now finally fall? There has also been positive news for Varta recently. Is the possible collaboration with Porsche a game changer? Analysts have a clear opinion on this matter. At Carbon Done Right Developments, investors are eagerly awaiting the AIM listing. Once it happens, the share price could explode, as the Company is working on an ecosystem within a billion-dollar market. Should you position yourself now? In any case, all three companies are working towards a breakthrough.
Read
Commented by Fabian Lorenz on July 4th, 2024 | 07:05 CEST
Takeover battle, boom, and price surge: Evotec, Siemens Energy, Royal Helium in focus
Is Evotec heading for a takeover battle? The share price crash has likely attracted private equity. Now, the biotech company is said to have hired an investment bank for defence plans. An order from the US Department of Defense comes at the right time. Helium is also likely to gain importance in the US. The noble gas is indispensable for quantum computers, rockets, and other high-tech applications. In Canada, Royal Helium is currently making the transition from explorer to producer. The share is ripe for a price surge. Siemens Energy's share price currently only knows the way up. And according to analysts, a further 50% is possible.
Read
Commented by Fabian Lorenz on July 3rd, 2024 | 07:00 CEST
Nel and Plug Power at the end? New hydrogen favourites like dynaCERT share?
Are Nel and Plug Power at the end? In any case, the latest company reports from the former hydrogen high-flyers are no longer causing share prices to soar. Investors have been disappointed too often, and both are still worth billions on the stock market. It is undisputed that hydrogen will play an important role in the energy mix of the future. But it may be time for new favourites such as the German Nucera and dynaCERT. The latter is currently strengthening its team with a former German Daimler manager and has reported another order. The Company does not want to reinvent the wheel but to reduce emissions from diesel vehicles. This seems to be easier to achieve in practice than the mega-projects of Nel & Co.
Read
Commented by Fabian Lorenz on June 26th, 2024 | 07:00 CEST
SMA Solar shocks! Nel with partnerships! Kraken Energy shares could benefit from billionaire Bill Gates!
While Siemens Energy shares are marching towards a yearly high, driven by a new billion-dollar order from Saudi Arabia, many other energy shares - especially those in the carbon-neutral sector - have been struggling all year. Is now the time to take an anti-cyclical approach to stocks that are at rock bottom? SMA Solar has hit a new 52-week low following its profit warning. What do the analysts say? Nel ASA has not yet succeeded in breaking free with the spin-off of its subsidiary Cavendish Hydrogen. The Norwegians are relying on strong partners with a focused business model. Kraken Energy currently offers an exciting entry opportunity. Billionaire Bill Gates is making headlines with the construction of a new nuclear power plant in the US. Uranium specialist Kraken Energy could also benefit from this.
Read
Commented by Fabian Lorenz on June 25th, 2024 | 07:00 CEST
300%-Opportunity, problems, and the German Chancellor: Bayer, BioNTech, and Cardiol Therapeutics
Bayer is making positive headlines for a change. Following takeovers in cell and gene therapy, the Company is investing in Berlin and has brought the renowned Charité Hospital on board. Federal Chancellor Olaf Scholz gives the go-ahead for the project. Can the share benefit from this? The sell-off in Cardiol Therapeutics shares after positive study results was a surprise. Analysts are enthusiastic, raising price targets and seeing 300% potential. On the other hand, BioNTech shares are currently not an obvious buy. And now there are also problems with the FDA in the US. This is causing alarm among shareholders and impacting the share.
Read
Commented by Fabian Lorenz on June 19th, 2024 | 07:00 CEST
Insider alert at Rheinmetall and Thyssenkrupp Nucera! Is First Hydrogen better than Nel?
Insiders are taking action after the Rheinmetall share slipped below the EUR 500 mark in the past few days. Following share purchases last week, more board members ordered shares at the start of this week. And there is also positive news on the operational side. There is also an insider alert at Thyssekrupp Nucera. Can the German hydrogen share stop the downward trend? And should First Hydrogen be preferred over Nel? There are good reasons for this. The Canadians' hydrogen commercial vehicle has now also impressed Amazon in practical tests. The news has gone under the radar in the current negative industry environment. This presents a buying opportunity, as EUR 500 million in annual revenue potential is offset by a EUR 30 million market capitalization.
Read